Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).
Trozzi R, Tuyaerts S, Annibali D, Herreros Pomares A, Boog L, Van Dam P, Leunen K, Deroose C, Trum H, Amant F. Trozzi R, et al. Among authors: deroose c. Int J Gynecol Cancer. 2024 Aug 5;34(8):1217-1224. doi: 10.1136/ijgc-2023-005229. Int J Gynecol Cancer. 2024. PMID: 38724237 Clinical Trial.
Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P, Deroose C, Souverijns G, Dymarkowski S, De Keyzer F, Vandecaveye V. Michielsen K, et al. Among authors: deroose c. Eur Radiol. 2014 Apr;24(4):889-901. doi: 10.1007/s00330-013-3083-8. Epub 2013 Dec 11. Eur Radiol. 2014. PMID: 24322510 Clinical Trial.
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
Floris G, Wozniak A, Sciot R, Li H, Friedman L, Van Looy T, Wellens J, Vermaelen P, Deroose CM, Fletcher JA, Debiec-Rychter M, Schöffski P. Floris G, et al. Clin Cancer Res. 2013 Feb 1;19(3):620-30. doi: 10.1158/1078-0432.CCR-12-2853. Epub 2012 Dec 11. Clin Cancer Res. 2013. PMID: 23231951 Free PMC article.
Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection.
Billiet C, Peeters S, Decaluwé H, Vansteenkiste J, Dooms C, Deroose CM, Hendrikx M, De Leyn P, Bulens P, Karim R, Le Péchoux C, Mebis J, De Ruysscher D. Billiet C, et al. Among authors: deroose cm. J Thorac Oncol. 2016 Nov;11(11):1940-1953. doi: 10.1016/j.jtho.2016.06.018. Epub 2016 Jul 5. J Thorac Oncol. 2016. PMID: 27393474 Free article.
Inflammation-Based Index and 68Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC.
Pauwels E, Van Binnebeek S, Vandecaveye V, Baete K, Vanbilloen H, Koole M, Mottaghy FM, Haustermans K, Clement PM, Nackaerts K, Van Cutsem E, Verslype C, Deroose CM. Pauwels E, et al. Among authors: deroose cm. J Nucl Med. 2020 Jul;61(7):1014-1020. doi: 10.2967/jnumed.119.236935. Epub 2019 Dec 5. J Nucl Med. 2020. PMID: 31806775 Free article.
Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.
Vandecaveye V, Dresen RC, Pauwels E, Van Binnebeek S, Vanslembrouck R, Baete K, Mottaghy FM, Clement PM, Nackaerts K, Van Cutsem E, Verslype C, De Keyzer F, Deroose CM. Vandecaveye V, et al. Among authors: deroose cm. Radiol Imaging Cancer. 2022 May;4(3):e210095. doi: 10.1148/rycan.210095. Radiol Imaging Cancer. 2022. PMID: 35621524 Free PMC article. Clinical Trial.
206 results